Seed targeting with tiny anti-miR-1297 inhibits EMT in melanoma cells

References

• Carter JH, Spaulding NR, Colligan BM, et al. Abstract 22: overexpression of PAK 1 is a favorable prognostic biomarker in malignant melanoma. Cancer Res. 2013;73:22–22.
   Google Scholar
• Saladi SV, Keenen B, Marathe HG, et al. Modulation of extracellular matrix/adhesion molecule expression by BRG1 is associated with increased melanoma invasiveness. Mol Cancer. 2010;9:280.
   PubMed Web of Science ®Google Scholar
• Balakrishnan A, Bleeker FE, Lamba S, et al. Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. Cancer Res. 2007;67:3545–3550.
   PubMed Web of Science ®Google Scholar
• Takata M, Lin J, Takayanagi S, et al. Genetic and epigenetic alterations in the differential diagnosis of malignant melanoma and spitzoid lesion. Br J Dermatol. 2007;156:1287.
   PubMed Web of Science ®Google Scholar
• Voura EB, Ramjeesingh RA, Montgomery AM, et al. Involvement of integrin alpha(v)beta(3) and cell adhesion molecule L1 in transendothelial migration of melanoma cells. Mol Biol Cell. 2001;12:2699–2710.
   PubMed Web of Science ®Google Scholar
• Cheng CF, Giaccia AJ, Powell MB. Abstract 3412: hypoxia induces EMT in primary melanoma and MET in metastatic melanoma. Cancer Res. 2011;71:3412–3412.
   Web of Science ®Google Scholar
• Kuphal S, Bosserhoff AK. Influence of the cytoplasmic domain of E-cadherin on endogenous N-cadherin expression in malignant melanoma. Oncogene. 2006;25:248–259.
   PubMed Web of Science ®Google Scholar
• Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature. 2007;445:851–857.
   PubMed Web of Science ®Google Scholar
• Hao M, Song F, Du X, et al. Advances in targeted therapy for unresectable melanoma: new drugs and combinations. Cancer Lett. 2015;359:1–8.
   PubMed Web of Science ®Google Scholar
• Tassone P, Tagliaferri P, Rossi M, et al. Genetics and molecular profiling of multiple myeloma: novel tools for clinical management? Eur J Cancer. 2006;42:1530–1538.
   PubMed Web of Science ®Google Scholar
• Sand M, Skrygan M, Georgas D, et al. The miRNA machinery in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases and benign melanocytic nevi. Cell Tissue Res. 2012;350:119–126.
   PubMed Web of Science ®Google Scholar
• Li X, Wang HL, Peng X, et al. miR-1297 mediates PTEN expression and contributes to cell progression in LSCC. Biochem Biophys Res Commun. 2012;427:254–260.
   PubMed Web of Science ®Google Scholar
• Liu C, Wang C, Wang J, et al. miR-1297 promotes cell proliferation by inhibiting RB1 in liver cancer. Oncol Lett. 2016;12:5177–5182.
   PubMed Web of Science ®Google Scholar
• Yang NQ, Luo XJ, Zhang J, et al. Crosstalk between Meg3 and miR-1297 regulates growth of testicular germ cell tumor through PTEN/PI3K/AKT pathway. Am J Transl Res. 2016;8:1091.
   PubMed Web of Science ®Google Scholar
• Wang Z, He S, Guo P, et al. MicroRNA-1297 inhibits metastasis and epithelial–mesenchymal transition by targeting AEG-1 in cervical cancer. Oncol Rep. 2017;38:3121–3129.
   PubMed Web of Science ®Google Scholar
• Jønson L, Christiansen J, Hansen TV, et al. IMP3 RNP safe houses prevent miRNA-directed HMGA2 mRNA decay in cancer and development. Cell Rep. 2014;7:539–551.
   PubMed Web of Science ®Google Scholar
• Fung-Yu H, Danny Ka-Ho W, Wai-Kay S, et al. Estradiol induces apoptosis via activation of miRNA-23a and p53: implication for gender difference in liver cancer development. Oncotarget. 2015;6:34941–34952.
   PubMedGoogle Scholar
• Wartlick H, Michaelis K, Balthasar S, et al. Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J Drug Target. 2004;12:461–471.
   PubMed Web of Science ®Google Scholar
• Trajkovski M, Hausser J, Soutschek J, et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature. 2011;474:649.
   PubMed Web of Science ®Google Scholar
• Iorio MV, Croce CM. microRNA involvement in human cancer. Carcinogenesis. 2012;33:1126.
   PubMed Web of Science ®Google Scholar
• Philippidou D, Schmitt M, Moser D, et al. Signatures of microRNAs and selected microRNA target genes in human melanoma. Cancer Res. 2010;70:4163.
   PubMed Web of Science ®Google Scholar
• Reuland SN, Smith SM, Bemis LT, et al. MicroRNA-26a is strongly downregulated in melanoma and induces cell death through repression of silencer of death domains (SODD). J Invest Dermatol. 2013;133:1286.
   PubMed Web of Science ®Google Scholar
• Gibson NW. Engineered microRNA therapeutics. J Roy Coll Physicians Edinb. 2014;44:196.
   PubMedGoogle Scholar
• van Rooij E, Kauppinen S. Development of microRNA therapeutics is coming of age. Embo Mol Med. 2014;6:851.
   PubMed Web of Science ®Google Scholar
• Zheng J, Yi D, Shi X, et al. miR-1297 regulates neural stem cell differentiation and viability through controlling Hes1 expression. Cell Prolif. 2017;50:e12347.
   Web of Science ®Google Scholar
• Sebti SM. Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy. Cancer Cell. 2005;7:297–300.
   PubMed Web of Science ®Google Scholar
• Xiang XJ, Deng J, Liu YW, et al. MiR-1271 inhibits cell proliferation, invasion and EMT in gastric cancer by targeting FOXQ1. Cell Physiol Biochem. 2015;36:1382–1394.
   PubMed Web of Science ®Google Scholar
• Tumbarello DA, Brown MC, Hetey SE, et al. Regulation of paxillin family members during epithelial–mesenchymal transformation: a putative role for paxillin delta. J Cell Sci. 2005;118:4849.
   PubMed Web of Science ®Google Scholar
• Caramel J, Papadogeorgakis E, Hill L, et al. A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer Cell. 2013;24:466–480.
   PubMed Web of Science ®Google Scholar
• Hur K, Toiyama Y, Takahashi M, et al. MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut. 2013;62:1315–1326.
   PubMed Web of Science ®Google Scholar
• Chaw SY, Majeed AA, Dalley AJ, et al. Epithelial to mesenchymal transition (EMT) biomarkers – E-cadherin, beta-catenin, APC and Vimentin – in oral squamous cell carcinogenesis and transformation. Oral Oncol. 2012;48:997–1006.
   PubMed Web of Science ®Google Scholar
• Morel AP, Hinkal GW, Thomas C, et al. EMT inducers catalyze malignant transformation of mammary epithelial cells and drive tumorigenesis towards claudin-low tumors in transgenic mice. Plos Genet. 2012;8:e1002723.
   PubMed Web of Science ®Google Scholar
• Spaderna S, Schmalhofer O, Hlubek F, et al. A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology. 2006;131:830.
   PubMed Web of Science ®Google Scholar
• Dankort D, Curley DP, Cartlidge RA, et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet. 2009;41:544–552.
   PubMed Web of Science ®Google Scholar
• Wu H, Goel V, Haluska FG. PTEN signaling pathways in melanoma. Oncogene. 2003;22:3113–3122.
   PubMed Web of Science ®Google Scholar
• Guldberg P, Straten PT, Birck A, et al. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res. 1997;57:3660–3663.
   PubMed Web of Science ®Google Scholar
• Lin K, Baritaki S, Militello L, et al. The role of B-RAF mutations in melanoma and the induction of EMT via dysregulation of the NF-κB/Snail/RKIP/PTEN circuit. Genes Cancer. 2010;1:409–420.
   PubMedGoogle Scholar